Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience
- 300 Downloads
The impact of preoperative use of TNF-alpha inhibitors on postoperative complications in patients with inflammatory bowel disease (IBD) undergoing abdominal surgery is controversial. The aim of this study was to evaluate the 30-day postoperative outcomes for IBD patients treated with these drugs prior to surgery.
We analyzed retrospectively the incidence of short-term postoperative complications. Statistical analyses were performed to reveal the independent variables that influenced postoperative complications and the role of preoperative medical therapy with anti-TNF drugs within 12 weeks prior to surgery.
One hundred fourteen patients (76 with Crohn's disease (CD) and 38 ulcerative colitis (UC)) underwent abdominal surgery for IBD. Fifty-four patients were treated with anti-TNF-alpha within 12 weeks prior to surgery (anti-TNF group). Postoperative mortality and morbidity were 0% and 21%, respectively. The infection rate was 15%. A significantly higher incidence of postoperative complications was found in patients treated with high-dose steroids (58% vs. 17%; p = 0.003) after univariate analysis. The infection rate was significantly higher in patients treated with high-dose corticosteroids (50% vs. 11%; p = 0.002) and concomitant anti-TNF-alpha (60% vs. 13%; p = 0.023). Multivariate analysis revealed that only therapy with high-dose corticosteroids was significantly associated with cumulative (p = 0.017) and infective postoperative complications (p = 0.046). No significant differences were found between the anti-TNF group and the control group.
High-dose corticosteroids increased the risk of short-term postoperative cumulative and infective complications. Anti-TNF drugs within 12 weeks prior to abdominal surgery in patients with IBD did not appear to increase the rate of postoperative complications.
KeywordsAnti-TNF-alpha drugs Corticosteroids Ulcerative colitis Crohn's disease Postoperative complications
- 3.Orlando A, Armuzzi A, Papi C, The Italian Society of Gastroenterology (SIGE) and The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) et al (2011) Clinical Practice Guideline: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 43:1–20PubMedCrossRefGoogle Scholar
- 4.D’Haens G, Baert F, Van Assche G, Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667PubMedCrossRefGoogle Scholar
- 14.Brzezinski A, Armstrong l, De Real GA et al (2002) Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn’s disease. Gastroenterology 122:A617Google Scholar
- 15.Kasparek MS, Bruckmeier A, Beigel F, et al (2010) Effect of infliximab on postoperative complications in patients with Crohn ‘s disease undergoing abdominal surgery. Abstract DDWGoogle Scholar
- 22.Coquet-Reinier B, Berdah SV, Grimaud JC, et al (2010) Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg EndoscGoogle Scholar
- 24.Nestorov I (2005) Clinical pharmacokinetics of TNF antagonist: how do they differ? Sem Art RheumGoogle Scholar
- 28.Blonski W, Osterman MT, Lin MV, et al (2010) Risk of postoperative infections in IBD patients treated with perioperative anti-TNF therapy: a meta-analysis. Abstract DDWGoogle Scholar